Hepatology. 2024 May 8. doi: 10.1097/HEP.0000000000000913. Online ahead of print.

ABSTRACT

Metabolic-dysfunction associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is increasingly recognized as a prevalent global burden. Type 2 diabetes mellitus (T2DM), another important metabolic disease, is considered a major contributor to the development of MASLD. MASLD and T2DM have a strong association with each other due to shared pathogenic mechanisms. The co-existence of the two diseases increases the risk of liver-related adverse outcomes, and imposes a heavier burden on extrahepatic outcomes, representing a substantial public health issue. Effective assessment and management of T2DM combined with MASLD necessitate a multidisciplinary approach. The emergence of numerous randomized clinical trials has shed light on the treatment of T2DM combined with MASLD. This review uncovered the epidemiology of the intertwined T2DM and MASLD, offer insights into the evaluation of hepatic fibrosis in T2DM patients, glucose monitoring in MASLD population, and provide comprehensive co-management strategies for addressing both diseases.

PMID:38722246 | DOI:10.1097/HEP.0000000000000913